Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 1
2011 1
2013 2
2014 2
2016 1
2017 1
2018 3
2019 2
2020 2
2021 1
2022 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreatic cancer.
Brown BA, Myers PJ, Adair SJ, Pitarresi JR, Sah-Teli SK, Campbell LA, Hart WS, Barbeau MC, Leong K, Seyler N, Kane W, Lee KE, Stelow E, Jones M, Simon MC, Koivunen P, Bauer TW, Stanger BZ, Lazzara MJ. Brown BA, et al. Among authors: adair sj. Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-22-2945. Online ahead of print. Cancer Res. 2024. PMID: 38471099
ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer.
Ozturk H, Cingoz H, Tufan T, Yang J, Adair SJ, Tummala KS, Kuscu C, Kinali M, Comertpay G, Nagdas S, Goudreau BJ, Luleyap HU, Bingul Y, Ware TB, Hwang WL, Hsu KL, Kashatus DF, Ting DT, Chandel NS, Bardeesy N, Bauer TW, Adli M. Ozturk H, et al. Among authors: adair sj. Dev Cell. 2022 Jun 6;57(11):1331-1346.e9. doi: 10.1016/j.devcel.2022.04.014. Epub 2022 May 3. Dev Cell. 2022. PMID: 35508175 Free article.
Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth.
Nagdas S, Kashatus JA, Nascimento A, Hussain SS, Trainor RE, Pollock SR, Adair SJ, Michaels AD, Sesaki H, Stelow EB, Bauer TW, Kashatus DF. Nagdas S, et al. Among authors: adair sj. Cell Rep. 2019 Aug 13;28(7):1845-1859.e5. doi: 10.1016/j.celrep.2019.07.031. Cell Rep. 2019. PMID: 31412251 Free PMC article.
CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.
Michaels AD, Newhook TE, Adair SJ, Morioka S, Goudreau BJ, Nagdas S, Mullen MG, Persily JB, Bullock TNJ, Slingluff CL Jr, Ravichandran KS, Parsons JT, Bauer TW. Michaels AD, et al. Among authors: adair sj. Clin Cancer Res. 2018 Mar 15;24(6):1415-1425. doi: 10.1158/1078-0432.CCR-17-2283. Epub 2017 Dec 29. Clin Cancer Res. 2018. PMID: 29288236 Free PMC article.
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Wei X, Yang J, Adair SJ, Ozturk H, Kuscu C, Lee KY, Kane WJ, O'Hara PE, Liu D, Demirlenk YM, Habieb AH, Yilmaz E, Dutta A, Bauer TW, Adli M. Wei X, et al. Among authors: adair sj. Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28068-28079. doi: 10.1073/pnas.2009899117. Epub 2020 Oct 23. Proc Natl Acad Sci U S A. 2020. PMID: 33097661 Free PMC article.
20 results